Method for obtaining platelets by inducing iPSC (induced pluripotent stem cells) differentiation

Through the use of multi-stage culture system and specific compounds, the differentiation efficiency of iPSC to platelets is improved, the problems of low differentiation efficiency and risk of immune response are solved, and high-yield functional platelet production is achieved, providing feasibility for clinical applications.

CN118931833APending Publication Date: 2024-11-12ALLIFE REGENERATIVE MEDICINE TECH BEIJING CO LTD

Patent Information

Application Number
CN202410569490.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-09
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art has low differentiation efficiency when inducing iPSC differentiation to obtain platelets, and the use of mouse embryonic fibroblasts and serum has a risk of immunogenic reactions, which limits the scalability and clinical applicability of platelet supply.

Method used

A multi-stage culture system is adopted, including iPSC differentiation to form embryoid bodies, embryoid bodies towards mesoderm, mesoderm towards hematogenous endothelial cells, hematogenous endothelial cells towards myeloid progenitor cells, myeloid progenitor cells towards megokurogenesis, mesoderm towards megokurogenesis, mesoderm towards megokurogenesis, mesoderm towards megokurogenesis Differentiation of mature megakaryocytes and megakaryocytes into platelets, using specific compounds such as ROCK pathway inhibitors, GSK3β inhibitors and growth factors, to replace the traditional cell feeding layer and increase the yield of megakaryocytes and platelets.

Benefits of technology

The differentiation efficiency of iPSC to megakaryotic cells and platelets was significantly improved, and the yield increased to 1500-3000 megakaryotic progenitor cells and 15000-30000 platelets, reducing the culture cost, overcoming the problems of low differentiation efficiency and risk of immune response, and for a large scale The production of functional platelets laid the foundation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931833A_ABST
    Figure CN118931833A_ABST
Patent Text Reader

Abstract

The invention discloses a method for obtaining platelets by inducing iPSC differentiation, by adopting the method provided by the invention, 1500-3000 megakaryocyte progenitor cells can be obtained by one iPSC, compared with the current 20-50 megakaryocyte progenitor cells, the yield is obviously improved, 15000-3000 platelets can be finally obtained by one iPSC, and the method has the advantages that the cost is low, the cost is low, and the application prospect is wide. The technical problem that in the prior art, the differentiation efficiency of the iPSC to megakaryocytes and / or platelets is low is solved, a foundation is laid for large-scale production of functional platelets for biomedicine and clinical treatment, and the clinical application prospect is wide.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular, relates to a method for inducing iPSC differentiation to obtain platelets. Background Art

[0002] The vital processes of blood clotting and hemostasis rely on an adequate supply of platelets in the human blood. Blood transfusion remains the most effective method to increase a patient's platelet count, but limited platelet supply is an ongoing problem. The limited shelf life (5 days) and requirement for room temperature storage increase the risk of bacterial contamination and pose a significant challenge to maintaining an adequate supply. In addition, patients who receive multiple platelet transfusions, such as those with various types of cancer, often develop platelet refractory due to HLA alloreactivity and subsequently require additional transfusions of HLA-matched donor platelets. Finding alternative sources of non-immunogenic, high-quality platelets could help alleviate the chronic shortage of platelet supply and reduce the risk of refractory disease.

[0003] In this context, researchers have begun to develop in vitro platelet induction technology. Human embryonic stem cells (hESC), induced pluripotent stem cells (iPSC), and hematopoietic stem cells are the main sources of macrophages and functional platelets. However, the initial methods all relied on mouse embryonic fibroblast (MEF) feeder layers and serum at some point in the culture process. Because both MEF and serum may be contaminated with xenobiotics, their use increases the risk of immunogenic reactions in humans.

[0004] "Feeder-free" alternatives to MEFs, including Matrigel (BD), CELLstart (Life Technologies), recombinant proteins, and synthetic polymers, can be used to maintain and proliferate human pluripotent stem cells (hPSCs). However, feeder-free hPSCs undergo massive cell death during embryoid body (EB) formation, greatly reducing their potential to differentiate into all cell lineages. Ono Y. et al. (Induction of functional platelets from mouse and human fibroblasts by p45NF-E2 / Maf) used retroviral infection of three genes to transform human dermal fibroblasts into macrophage-like cells without reprogramming to a pluripotent state, and these MK-like cells only produced platelet-like particles when injected into immunodeficient mice. The use of viral vectors and the inability to produce platelets from macrophage-like cells in vitro limit the clinical applicability of this method. None of the above methods are sufficient to provide expandable and / or fully functional platelets for clinical use. Considering that a transfusion unit contains approximately 300-600×10 9If the in vitro method is to be applied clinically, its efficiency needs to be greatly improved. Summary of the invention

[0005] In view of this, the purpose of the present invention is to provide a method for inducing iPSC differentiation to obtain platelets, so as to overcome the above technical problems existing in the art. The method can significantly increase the yield of megakaryocytes and reduce the culture cost.

[0006] By using the method provided by the present invention, 1 iPSC can obtain 1500 to 3000 megakaryocyte progenitor cells, which is a significant improvement in yield compared to the current result of 20-50. One iPSC can ultimately produce 15,000-30,000 platelets, overcoming the technical problem of low differentiation efficiency of iPSC into megakaryocytes and / or platelets faced by the prior art, laying the foundation for large-scale production of functional platelets for biomedicine and clinical treatment, and having broad prospects for clinical application.

[0007] The above-mentioned object of the present invention is achieved through the following technical solutions:

[0008] A first aspect of the present invention provides a culture system for inducing iPSC differentiation to obtain megakaryocytes and / or platelets.

[0009] Further, the culture system includes a culture medium for iPSC differentiation to form embryoid bodies, a culture medium for embryoid bodies to differentiate into mesoderm, a culture medium for mesoderm to differentiate into hemogenic endothelial cells, a culture medium for hemogenic endothelial cells to differentiate into myeloid progenitor cells, a culture medium for myeloid progenitor cells to differentiate into megakaryotic progenitor cells, a culture medium for megakaryotic progenitor cells to differentiate into mature megakaryocytes, and / or a culture medium for megakaryocytes to differentiate into platelets;

[0010] Preferably, the iPSC differentiation to form embryoid bodies culture medium comprises a basal culture medium, a ROCK pathway inhibitor, and PVA;

[0011] Preferably, the embryoid body to mesoderm differentiation medium comprises a basal medium and a GSK3β inhibitor;

[0012] Preferably, the mesoderm to hemogenic endothelial cell differentiation medium comprises M1 medium and M2 medium;

[0013] Preferably, the medium for differentiating hemogenic endothelial cells into myeloid progenitor cells comprises M3 medium;

[0014] Preferably, the culture medium for differentiating myeloid progenitor cells into megakaryotic progenitor cells comprises M4 culture medium;

[0015] Preferably, the medium for differentiating megakaryocyte progenitor cells into mature megakaryocytes comprises M5 medium;

[0016] Preferably, the megakaryocyte differentiation platelet formation medium comprises M6 medium;

[0017] More preferably, the basal medium in the iPSC differentiation to form embryoid bodies culture medium includes E8 medium, complete medium, StemSpan TM SFEM Hematopoietic Cell Culture Medium、StemPro-34、 II. STEMdiff TM APEL TM 2 Medium and / or BPEL;

[0018] More preferably, the ROCK pathway inhibitor includes Y-27632, Thiazovivin, Fasudil HCl, GSK429286A, RKI-1447, and / or Azaindole 1;

[0019] Most preferably, the basal medium in the iPSC differentiation to form embryoid bodies culture medium is E8 medium or complete medium;

[0020] Most preferably, the ROCK pathway inhibitor is Y-27632;

[0021] Most preferably, the iPSC differentiation to form embryoid bodies culture medium is E8 culture medium containing Y-27632 or complete culture medium containing PVA;

[0022] More preferably, the basal medium in the embryoid body to mesoderm differentiation medium includes E8 medium, complete medium, StemSpan TM SFEM Hematopoietic Cell Culture Medium、StemPro-34、 II. STEMdiff TM APEL TM 2 Medium and / or BPEL;

[0023] More preferably, the GSK3β inhibitor includes Chir99021, SB216763, CHIR-98014, TWS119, Tideglusib, and / or SB415286;

[0024] Most preferably, the basal medium in the embryoid body to mesoderm differentiation medium is E8 medium;

[0025] Most preferably, the GSK3β inhibitor is Chir99021;

[0026] Most preferably, the embryoid body to mesoderm differentiation medium is E8 complete medium containing Chir99021;

[0027] Preferably, the M1 medium in the mesoderm-to-hemogenic endothelial cell differentiation medium contains STEMdiff TM APEL TM 2 Medium or (DMEM / F12, IMDM, L-glutamine, ascorbic acid, monothioglycerol, PFHMII, BSA or HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine), BMP4, VEGF, bFGF;

[0028] Preferably, the M2 medium in the mesoderm-to-hemogenic endothelial cell differentiation medium comprises M1 medium, inhibitors of TGF-β type I receptor ALK5, ALK4 and ALK7;

[0029] More preferably, the inhibitors of TGF-β type I receptor ALK5, ALK4 and ALK7 include SB431542, Galunisertib, LY2109761, SB525334, SB505124, and / or GW788388;

[0030] Most preferably, the inhibitor of TGF-β type I receptor ALK5, ALK4 and ALK7 is SB431542;

[0031] Preferably, the M3 medium in the hemogenic endothelial cell differentiation medium to myeloid progenitor cell contains APEL or (DMEM / F12, IMDM, L-glutamine, ascorbic acid, thioglycerol, PFHMII, BSA or HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine), β-mercaptoethanol, VEGF, bFGF, SCF, IL-3, TPO, IL-6, IL-11;

[0032] Preferably, the M4 medium in the medium for differentiation of myeloid progenitor cells into megakaryocyte progenitor cells contains StemSpan TM SFEM Hematopoietic Cell Culture Medium or STEMdiff TM APEL TM2 Medium or (DMEM / F12, IMDM, L-glutamine, ascorbic acid, monothioglycerol, PFHMII, BSA or HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine), IL-6, IL-11, SCF, sodium heparin, TPO or TA316;

[0033] Preferably, the M5 medium in the medium for differentiating megakaryocyte progenitor cells into mature megakaryocytes contains IMDM, serum, L-glutamine, ascorbic acid, 1×Insulin-Transferrin-Selenium-Ethanolamine, thioglycerol, SCF, TA316 or TPO, GM6001, SR1, Y-27632, (-)-Blebbistatin;

[0034] More preferably, the serum comprises FBS, KSR, HSA, and / or HPL;

[0035] Most preferably, the serum is FBS;

[0036] Preferably, the M6 ​​medium in the megakaryocyte differentiation medium to form platelets contains IMDM, serum, L-glutamine, ascorbic acid, 1×Insulin-Transferrin-Selenium-Ethanolamine, thioglycerol, SCF, TA316 or TPO, GM6001, SR1, and Y-27632;

[0037] More preferably, the serum comprises FBS, KSR, HSA, and / or HPL;

[0038] Most preferably, the serum is FBS.

[0039] Furthermore, the contents of the components in the iPSC differentiation to form embryoid bodies culture medium are: (1-50) μM Y-27632, (0.05-10) mg / mL PVA;

[0040] Preferably, the contents of the components in the iPSC differentiation to form embryoid bodies medium are: 10 μM Y-27632, 2 mg / mL PVA;

[0041] Preferably, the contents of the components in the embryoid body to mesoderm differentiation medium are: (1-10) μM Chir99021;

[0042] More preferably, the contents of the components in the embryoid body to mesoderm differentiation medium are: 10 μM Chir99021;

[0043] Preferably, the contents of the components in the M1 medium in the mesoderm-to-hemogenic endothelial cell differentiation medium are: TM APEL TM 2 Medium or (35-55)% DMEM / F12, (35-55)% IMDM, (0.01-10)% L-glutamine, (25-75) μg / mL ascorbic acid, (0.05-10) mM thioglycerol, (1-10)% PFHMII, (1-10) mg / mL BSA or (0.05-10)% HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine, (25-75) ng / mL BMP4, (25-75) ng / mL VEGF, (25-75) ng / mL bFGF;

[0044] More preferably, the contents of the components in the M1 medium in the mesoderm-to-hemogenic endothelial cell differentiation medium are: TM APEL TM 2 Medium or 44.15% DMEM / F12, 44.15% IMDM, 1% L-glutamine, 50μg / mL ascorbic acid, 0.4mM thioglycerol, 5% PFHMII, 2.5mg / mL BSA or 1.25% HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine, 50ng / mL BMP4, 50ng / mL VEGF, 50ng / mL bFGF;

[0045] Preferably, the content of SB431542 in the M2 medium in the mesoderm-to-hemogenic endothelial cell differentiation medium is: (1-9) μM;

[0046] More preferably, the content of SB431542 in the M2 medium in the mesoderm to hemogenic endothelial cell differentiation medium is: 6 μM;

[0047] Preferably, the contents of the components in the M3 medium in the hemogenic endothelial cell to myeloid progenitor cell differentiation medium are: APEL or (35-55)% DMEM / F12, (35-55)% IMDM, (0.01-10)% L-glutamine, (25-75) μg / mL ascorbic acid, (0.05-10) mM thioglycerol, (1-10)% PFHMII, (1-10) mg / mL BSA or (0.05-10)% HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine, (25-75) μM β-mercaptoethanol, (25-75) ng / mL VEGF, (25-75) ng / mL bFGF, (25-75) ng / mL SCF, (1-50) ng / mL IL-3, (25-75) ng / mL TPO, (1-50)ng / mL IL-6, (1-50)ng / mL IL-11;

[0048] More preferably, the contents of the components in the M3 medium in the hemogenic endothelial cell to myeloid progenitor cell differentiation medium are: APEL or 44.15% DMEM / F12, 44.15% IMDM, 1% L-glutamine, 50 μg / mL ascorbic acid, 0.4 mM thioglycerol, 5% PFHMII, 2.5 mg / mL BSA or 1.25% HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine, 55 μM β-mercaptoethanol, 50 ng / mL VEGF, 50 ng / mL bFGF, 50 ng / mL SCF, 20 ng / mL IL-3, 50 ng / mL TPO, 20 ng / mL IL-6, 20 ng / mL IL-11;

[0049] Preferably, the contents of the components in the M4 medium in the medium for myeloid progenitor cells to differentiate into megakaryocyte progenitor cells are: StemSpan TM SFEM Hematopoietic Cell Culture Medium or STEMdiff TM APEL TM2Medium or (35-55)% DMEM / F12, (35-55)% IMDM, (0.01-10)% L-glutamine, (25-75) μg / mL ascorbic acid, (0.05-10) mM thioglycerol, (1-10)% PFHMII, (1-10) mg / mL BSA or (0.05-10)% HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine, (1-50) ng / mL IL-6, (1-50) ng / mL IL-11, (25-75) ng / mL SCF, (1-50) U / mL heparin sodium, (25-75) ng / mL TPO or (100-300) ng / mL TA316;

[0050] More preferably, the contents of the components in the M4 medium in the medium for myeloid progenitor cells to differentiate into megakaryocyte progenitor cells are: StemSpan TM SFEM Hematopoietic Cell Culture Medium or STEMdiff TM APEL TM 2Medium or 44.15% DMEM / F12, 44.15% IMDM, 1% L-glutamine, 50μg / mL ascorbic acid, 0.4mM thioglycerol, 5% PFHMII, 2.5mg / mL BSA or 1.25% HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine, 20ng / mL IL-6, 20ng / mL IL-11, 50ng / mL SCF, 10U / mL heparin sodium, 50ng / mL TPO or 200ng / mL TA316;

[0051] Preferably, the contents of the components in the M5 medium in the medium for differentiating megakaryocyte progenitor cells into mature megakaryocytes are: IMDM, (2-20)% FBS, (0.01-10)% L-glutamine, (25-75) μg / mL ascorbic acid, 1×Insulin-Transferrin-Selenium-Ethanolamine, (0.01-10) mM thioglycerol, (1-50) ng / mL SCF, (100-300) ng / mL TA316 or (25-75) ng / mL TPO, (1-50) μM GM6001, (0.01-5) μM SR1, (1-20) μM Y-27632, (1-20) μM (-)-Blebbistatin;

[0052] More preferably, the contents of the components in the M5 medium in the medium for differentiating megakaryocyte progenitor cells into mature megakaryocytes are: IMDM, 5% FBS, 1% L-glutamine, 50 μg / mL ascorbic acid, 1×Insulin-Transferrin-Selenium-Ethanolamine, 0.4 mM thioglycerol, 20 ng / mL SCF, 200 ng / mL TA316 or 50 ng / mL TPO, 20 μM GM6001, 0.75 μM SR1, 10 μM Y-27632, 10 μM (-)-Blebbistatin;

[0053] Preferably, the contents of the components in the M6 ​​medium in the megakaryocyte differentiation into platelet medium are: IMDM, (2-20)% FBS, (0.01-10)% L-glutamine, (25-75) μg / mL ascorbic acid, 1×Insulin-Transferrin-Selenium-Ethanolamine, (0.01-5) mM thioglycerol, (1-50) ng / mL SCF, (100-300) ng / mL TA316 or (25-75) ng / mL TPO, (1-50) μM GM6001, (0.01-5) μM SR1, (1-20) μM Y-27632;

[0054] More preferably, the contents of the components in the M6 ​​medium in the megakaryocyte differentiation into platelet medium are: IMDM, 5% FBS, 1% L-glutamine, 50 μg / mL ascorbic acid, 1×Insulin-Transferrin-Selenium-Ethanolamine, 0.4 mM thioglycerol, 20 ng / mL SCF, 200 ng / mL TA316 or 50 ng / mL TPO, 20 μM GM6001, 0.75 μM SR1, and 10 μM Y-27632.

[0055] A second aspect of the present invention provides a method for inducing iPSC differentiation to obtain megakaryocytes and / or platelets.

[0056] Furthermore, the method comprises the following steps: culturing and differentiating iPSCs using the culture system described in the first aspect of the present invention.

[0057] Furthermore, the method specifically comprises the following steps:

[0058] (1) Day-1, iPSC differentiation to form embryoid bodies stage, iPSCs are cultured using the iPSC differentiation to form embryoid bodies medium described in the first aspect of the present invention;

[0059] (2) Day 0, embryoid body differentiation to mesoderm stage, the culture product obtained in step (1) is cultured using the embryoid body to mesoderm differentiation medium described in the first aspect of the present invention;

[0060] (3) Day 1 to Day 3, the stage of differentiation of mesoderm into hemogenic endothelial cells, using the M1 medium and M2 medium described in the first aspect of the present invention to culture the culture product obtained in step (2);

[0061] (4) Day 4 to Day 12, the stage of differentiation of hemogenic endothelial cells into myeloid progenitor cells, culturing the culture product obtained in step (3) using the M3 medium described in the first aspect of the present invention;

[0062] (5) Day 12-Day 15, myeloid progenitor cells differentiate into megakaryotic progenitor cells, and the culture product obtained in step (4) is cultured using the M4 medium described in the first aspect of the present invention;

[0063] (6) Day 15-Day 17, the stage of differentiation of megakaryocyte progenitor cells into mature megakaryocytes, the culture product obtained in step (5) is cultured using the M5 medium described in the first aspect of the present invention;

[0064] (7) Day 17, the stage of megakaryocyte differentiation into platelets, the culture product obtained in step (6) is cultured using the M6 ​​culture medium described in the first aspect of the present invention to obtain platelets.

[0065] Furthermore, the cell density of the iPSCs in step (1) is 1.0×10 5 -2×10 5 / mL;

[0066] Preferably, the culture conditions are 5% CO2, 37°C, 24h;

[0067] Preferably, the culture conditions in step (2) are 5% CO2, 90% N2, 37°C, 24h;

[0068] Preferably, step (3) comprises the following steps: Day 1, replacing the culture medium with M1 culture medium; Day 2, replacing the culture medium with M2 culture medium; Day 3, half-changing the culture medium;

[0069] More preferably, the culture conditions in step (3) are 5% CO2, 90% N2, 37°C, 24h.

[0070] Furthermore, the culture conditions in step (4) are 5% CO2 and 37°C;

[0071] Preferably, the culture conditions in step (4) are suspension culture or adherent culture;

[0072] More preferably, the adherent culture uses a cell culture dish pre-coated with a culture dish coating matrix;

[0073] Most preferably, the culture dish coating matrix comprises Matrigel, Geltin, Lamin521, and / or Fibronection;

[0074] Most preferably, the culture dish coating matrix is ​​Matrigel;

[0075] More preferably, the medium is changed once every 3.5 days in step (4);

[0076] Preferably, the culture conditions in step (5) are 5% CO2, 37°C;

[0077] Preferably, the cell density of the cells in step (5) is 1.0×10 4 -10×10 4 / mL;

[0078] More preferably, the cell density of the cells in step (5) is 5.0×10 4 / mL;

[0079] Preferably, the culture conditions in step (5) are suspension culture or adherent culture;

[0080] More preferably, the adherent culture is performed in an uncoated culture dish.

[0081] Furthermore, the culture conditions in step (6) are 5% CO2 and 37°C;

[0082] Preferably, the cell density of the cells in step (6) is 1.0×10 5 -3.0×10 5 / mL;

[0083] Preferably, the culture conditions in step (6) are suspension culture or adherent culture;

[0084] Preferably, the culture conditions in step (7) are 5% CO2, 37°C;

[0085] Preferably, the cell density of the cells in step (7) is 1.0×10 5 -10×10 5 / mL;

[0086] More preferably, the cell density of the cells in step (7) is 5×105 / mL;

[0087] Preferably, the culture conditions in step (7) are suspension culture or adherent culture.

[0088] A third aspect of the present invention provides any of the following methods:

[0089] (1) A method for improving the differentiation efficiency of iPSCs into megakaryocytes, the method comprising the following steps: culturing and differentiating iPSCs using the culture system described in the first aspect of the present invention;

[0090] Preferably, the steps are as described in the second aspect of the present invention. Steps (1) to (6);

[0091] (2) A method for improving the differentiation efficiency of iPSCs into platelets, the method comprising the following steps: culturing and differentiating iPSCs using the culture system described in the first aspect of the present invention;

[0092] Preferably, the steps are as described in steps (1) to (7) in the second aspect of the present invention.

[0093] A fourth aspect of the present invention provides the application of any of the following aspects:

[0094] (1) Use of the culture system described in the first aspect of the present invention in inducing iPSC differentiation to obtain megakaryocytes and / or platelets;

[0095] (2) Use of megakaryocytes and / or platelets prepared by the method described in the second aspect of the present invention in the preparation of drugs for treating diseases related to megakaryocyte and / or thrombocytopenia.

[0096] A fifth aspect of the present invention provides a pharmaceutical preparation.

[0097] Furthermore, the pharmaceutical preparation comprises megakaryocytes and / or platelets prepared by the method described in the second aspect of the present invention.

[0098] In some embodiments, the pharmaceutical preparation further comprises a pharmaceutically acceptable carrier and / or excipient, which includes but is not limited to: a diluent, a binder, a surfactant, a humectant, an adsorption carrier, a lubricant, a filler, and a disintegrant. These substances are used to help the stability of the formulation or to help improve the activity or its biological effectiveness as required. The preparation that can be used in this medicine can be in the form of its original compound itself, or optionally in the form of its pharmaceutically acceptable salt. The pharmaceutical preparation thus prepared can be administered in any appropriate manner known to those skilled in the art as required.

[0099] In the present invention, the dosage form of the pharmaceutical preparation is not particularly limited. In some embodiments, the drug can be prepared as an injection pharmaceutical preparation. Those skilled in the art can select a suitable dosage form known in the art according to actual needs (e.g., to improve the bioavailability of the drug, to improve the patient's medication compliance, etc.).

[0100] In some embodiments, the dosage suitable for the pharmaceutical preparation of the present invention can be prescribed in a variety of ways depending on factors such as the formulation method, administration method, patient's age, weight, gender, morbidity, diet, administration time, administration route, excretion rate and reaction sensitivity. A skilled physician can usually easily determine the prescription and the dosage that is effective for the desired treatment.

[0101] In addition, the present invention also provides a method for treating and / or preventing diseases related to low megakaryocytes and / or thrombocytopenia, the method comprising the following steps: administering to a subject in need thereof an effective amount of the pharmaceutical preparation provided by the present invention or the megakaryocytes and / or platelets prepared by the method described in the second aspect of the present invention.

[0102] In the present invention, the subject refers to any animal, including humans and non-human animals. Non-human animals include all vertebrates, for example, mammals, such as non-human primates (especially higher primates), sheep, dogs, rodents (such as mice or rats), guinea pigs, goats, pigs, cats, rabbits, cattle, and any livestock or pets; and non-mammals, such as chickens, amphibians, reptiles, etc. In a specific embodiment of the present invention, the subject is preferably a human.

[0103] In the present invention, the treatment and / or prevention refers to preventing and reducing the occurrence or development of the disease, so that the development or aggravation of the disease course can be inhibited, contained, alleviated, improved, slowed down, stopped, delayed or reversed. The various indicators of the disease, disorder or pathological state during maintenance and / or medication include alleviating or reducing the symptoms or complications of a specific disease, or curing or eliminating the disease, disorder or condition. Therefore, the treatment and / or prevention described in the present invention includes preventing, alleviating and / or treating the disease (for example: megakaryocyte and / or thrombocytopenia-related diseases).

[0104] In the present invention, the administration of the pharmaceutical preparation, megakaryocytes and / or platelets includes, but is not limited to, intravenous infusion, subcutaneous injection, intramuscular injection, oral administration, and intraperitoneal injection. In a specific embodiment of the present invention, the administration is preferably intravenous infusion.

[0105] In the present invention, the megakaryocyte and / or thrombocytopenia-related diseases refer to any disease with megakaryocyte and / or thrombocytopenia as the phenotype, including but not limited to: severe blood loss, anemia (including but not limited to: thalassemia, aplastic anemia, megaloblastic anemia), congenital amegakaryocytic thrombocytopenia (CAMT), primary immune thrombocytopenia (ITP), acquired thrombocytopenia (AITP), immune thrombocytopenic purpura, systemic lupus erythematosus, malignant lymphoma, upper respiratory tract infection, rubella, neonatal thrombocytopenia, Post-transfusion thrombocytopenia, DIC (disseminated intravascular coagulation), chronic liver disease with thrombocytopenia, thrombocytopenia caused by bone marrow transplantation after chemotherapy or radiotherapy, Paris-Trousseau thrombocytopenia, familial platelet disorder with myeloid leukemia, GATA1 mutant thrombocytopenia, giant platelet syndrome, gray platelet syndrome, Montreal platelet syndrome, leukemia, thrombocytopenia caused by severe infection (including but not limited to severe pneumonia, abdominal infection, etc.) or low megakaryocytes and / or platelets due to other reasons. BRIEF DESCRIPTION OF THE DRAWINGS

[0106] Figure 1 The morphological observations of iPSC, HE, HPC, MKP, MMK and PPF cells under an optical microscope during differentiation; iPSC is induced pluripotent stem cell, HE is hemogenic endothelial cell, HPC is myeloid progenitor cell (also called hematopoietic progenitor cell), MKP is megakaryocyte progenitor cell, MMK is mature megakaryocyte, and PPF is platelet precursor;

[0107] Figure 2 The results of CD34 expression test during the differentiation stage of mesoderm into hemogenic endothelial cells;

[0108] Figure 3 The results of the CD45 and CD34 expression test during the differentiation stage of hemogenic endothelial cells into myeloid progenitor cells;

[0109] Figure 4 The results of the detection of CD41a, CD42b, CD61, and CD34 expressions during the differentiation stage of myeloid progenitor cells into megakaryotic progenitor cells;

[0110] Figure 5 The results of the expression of CD41a, CD42b, CD61, and CD34 during the differentiation stage of megakaryocyte progenitor cells into mature megakaryocytes;

[0111] Figure 6 This is the Giemsa staining image of mature megakaryocytes;

[0112] Figure 7The results of cell number statistics and flow cytometry at different differentiation times of MKP and MMK stages are shown in Figure A: cell counts at different days of MKP and MMK; Figure B: flow cytometry detection of CD34- / CD61+ and CD41+ / CD42+ cell ratios at different days of MKP and MMK;

[0113] Figure 8 Detection of marker expression and platelet activation in iPSC-derived platelets and donor-derived platelets;

[0114] Fig. 9 Comparative detection of blood clot retraction between iPSC-derived platelets and donor-derived platelets;

[0115] Fig.10 Electron microscopic comparison of iPSC-derived platelets and donor-derived platelets;

[0116] Fig.11 Validation of in vivo circulation experiments of iPSC-derived platelets and donor-derived platelets in mice;

[0117] Fig.12 To detect the thrombosis function of iPSC-derived platelets;

[0118] Fig.13 To screen factors that can promote megakaryocyte maturation, Figure A: cell morphology; Figure B: proportion of cells with high CD61 expression; Figure C: CD41+ / CD42+ cell ratio;

[0119] Fig.14 These are the results of serum concentration optimization, where A: the proportion of each cell type; B: cell morphology; C: MMK and platelet calculation and statistical results at different serum concentrations; D: platelet activity at different serum concentrations. DETAILED DESCRIPTION

[0120] The present invention is further described below in conjunction with specific embodiments, which are only used to explain the present invention and cannot be understood as limiting the present invention. It can be understood by those skilled in the art that various changes, modifications, substitutions and variations can be made to these embodiments without departing from the principles and purpose of the present invention, and the scope of the present invention is defined by the claims and their equivalents.

[0121] The reagents and raw materials used in the present invention are easily obtained by ordinary technicians in the field and can be obtained from commercial channels unless otherwise specified. The experimental methods in the present invention that do not specify specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. In particular, the following examples are only used to illustrate the present invention and should not limit the scope of the present invention in any way.

[0122] Example 1 Preparation of Megakaryocytes and Platelets

[0123] 1. Differentiation of human pluripotent stem cells into embryoid bodies (Day-1)

[0124] (1) Induced pluripotent stem cells (iPSCs) were cultured, and when the confluence reached 70%, the supernatant was removed, and the cells were washed twice with preheated DPBS. Then, preheated Tryple was added to digest the cells to a single cell state. After terminating the digestion and centrifuging, the supernatant was removed, and E8 medium containing 10 μM Y-27632 and complete medium containing 2 mg / mL polyvinyl alcohol (PVA) were added to resuspend the cells and count the cells.

[0125] The iPSCs used in the present invention are prepared according to the method described in Chinese Patent Publication CN113462638A (eg, using the reprogramming factor combination OCT4, SOX2, E6 and E7).

[0126] (2) Adjust the iPSC cell density to 1.0×10 5 -2×10 5 / mL, inoculate cells into low-adsorption six-well plates, 3mL of culture medium per well, i.e., 0.3-0.6 million cells per well, and culture the cells in a 5% CO2, 37°C constant temperature incubator for 24 hours, recorded as Day-1.

[0127] In this embodiment, the ROCK pathway inhibitor is 0.5-20 μM Y-27632; other small molecules that can exert similar effects include Thiazovivin, Fasudil (HA-1077) HCl, GSK429286A, RKI-1447, and Azaindole 1.

[0128] 2. Differentiation of embryoid bodies into myeloid progenitor cells (Day 0-Day 12)

[0129] (1) Differentiation of embryoid bodies into mesoderm (Day 0)

[0130] The embryoid bodies (EBs) were transferred to a centrifuge tube, centrifuged at 20 g for 2 min, and the supernatant was removed. E8 complete medium containing 10 μM GSK3β inhibitor was added to initiate mesoderm differentiation, which was recorded as Day 0. The cells were cultured in a 5% CO2, 90% N2, 37°C constant temperature incubator for 24 h.

[0131] In this embodiment, the inhibitor of GSK3β is 1-10 μM Chir99021; other small molecules that can exert similar effects include SB216763, CHIR-98014, TWS119, Tideglusib, and SB415286.

[0132] In this embodiment, the differentiation induction basal medium includes but is not limited to StemSpan TM SFEMHematopoietic Cell Culture Medium、StemPro-34、 II. STEMdiff TM APEL TM 2Medium, BPEL.

[0133] (2) Differentiation of mesoderm into hemogenic endothelial cells (Day 1-Day 3)

[0134] a. Day 1, the culture medium was replaced with M1 medium, which was prepared by STEMdiff TM APEL TM 2Medium or (44.15% DMEM / F12, 44.15% IMDM, 1% L-glutamine, 50μg / mL ascorbic acid, 0.4mM thioglycerol, 5% PFHMII, 2.5mg / mL BSA or 1.25% HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine), 50ng / mL BMP4, 50ng / mL VEGF, 50ng / mL bFGF, and culture the cells in a constant temperature incubator at 5% CO2, 90% N2, 37°C for 24 hours.

[0135] b. Day 2, the culture medium was replaced with M2 medium. M2 medium was based on M1 medium with 6 μM SB431542 (an inhibitor of TGF-β type I receptor ALK5, ALK4 and ALK7). 3 mL was added to each well and the cells were cultured in a 5% CO2, 90% N2, 37°C constant temperature incubator for 24 hours.

[0136] c. Day 3, half-change the medium.

[0137] In this embodiment, the inhibitor of TGF-β type I receptor ALK5, ALK4 and ALK7 is 1-9 μM SB431542; other small molecules that can exert similar effects include Galunisertib (LY2157299), LY2109761, SB525334, SB505124, and GW788388.

[0138] (3) Differentiation of hemogenic endothelial cells into myeloid progenitor cells (Day 4-Day 12)

[0139] On Day 4, hemogenic endothelial cells were transferred to a cell culture dish coated with Matrigel in advance, and the M3 medium was replaced at the same time. The M3 medium consisted of APEL or (44.15% DMEM / F12, 44.15% IMDM, 1% L-glutamine, 50μg / mL ascorbic acid, 0.4mM thioglycerol, 5% PFHMII, 2.5mg / mL BSA or 1.25% HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine), 55μM β-mercaptoethanol, 50ng / mL VEGF, 50ng / mL bFGF, 50ng / mL SCF, 20ng / mL IL-3, 50ng / mL TPO, 20ng / mL IL-6 and 20ng / mL IL-11. The cells were cultured in a 5% CO2, 37°C constant temperature incubator until Day 12, and the medium was changed once every 3.5 days. Day 12: Collect the suspended cells for flow cytometry analysis.

[0140] In this embodiment, the culture dish coating matrix includes but is not limited to Mtrigel, Geltin, Lamin521 or Fibronection.

[0141] 3. Myeloid progenitor cells differentiate into megakaryotic progenitor cells (MKP) (Day 12-Day 15)

[0142] Day 12, transfer the suspended cells to a non-coated culture dish and adjust the cell density to 5.0×10 4 / mL, and the culture medium was replaced with M4 medium, which was composed of StemSpan TM SFEM Hematopoietic Cell CultureMedium or STEMdiff TM APEL TM 2 Medium or (44.15% DMEM / F12, 44.15% IMDM, 1% L-glutamine, 50μg / mL ascorbic acid, 0.4mM thioglycerol, 5% PFHMII, 2.5mg / mL BSA or 1.25% HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine basal medium), plus 20ng / mL IL-6, 20ng / mL IL-11, 50ng / mL SCF, 10U / mL heparin sodium, 50ng / mL TPO or 200ng / mL TA316, and culture the cells in a 5% CO2, 37℃ constant temperature incubator until Day 15.

[0143] 4. Megakaryotic progenitor cells differentiate into mature megakaryocytes (MMK) (Day 15-Day 17)

[0144] Day 15, adjust the cell density to 1.0×10 5 -3.0×10 5 / mL, and the culture medium was replaced with M5 medium, which consists of IMDM, 5% FBS (fetal bovine serum), 1% L-glutamine, 50μg / mL ascorbic acid, 1×Insulin-Transferrin-Selenium-Ethanolamine, 0.4mM thioglycerol, 20ng / mL SCF, 200ng / mL TA316 or 50ng / mL TPO, 20μM GM6001, 0.75μM SR1, 10μM Y-27632, and 10μM (-)-Blebbistatin. The cells were cultured in a 5% CO2, 37°C constant temperature incubator until Day 17.

[0145] In this embodiment, the serum in the culture medium can be replaced by KSR, HSA, HPL, etc.

[0146] 5. Megakaryocytes differentiate into platelets

[0147] Day 17, start inducing platelet precursors and platelet formation. Adjust the cell density to 5×10 5 / mL, resuspended in platelet formation medium M6. M6 medium consists of IMDM, 5% FBS, 1% L-glutamine, 50μg / mL ascorbic acid, 1×Insulin-Transferrin-Selenium-Ethanolamine, 0.4mM thioglycerol, 20ng / mL SCF, 200ng / mL TA316 or 50ng / mL TPO, 20μM GM6001, 0.75μM SR1, 10μM Y-27632, and cultured the cells in a 5% CO2, 37°C constant temperature incubator for 2 days, or in a shaking incubator, shaking and culturing at 120rpm for 2 days. Platelets were harvested 2 days after induction for marker identification and functional testing.

[0148] In this embodiment, the fetal bovine serum (FBS) in the culture medium can be replaced by KSR, HSA, HPL, etc.

[0149] 6. Experimental results

[0150] The experimental results are as follows Figure 1-6As shown in the figure, the EBs formed obvious cavities with smooth edges in the HE stage of differentiation, a large number of suspended cells appeared around the EBs in the HSC stage of differentiation, and the cells proliferated significantly in the megakaryocyte progenitor stage, with a small number of large cells. In the mature megakaryocyte stage of differentiation, a large number of large megakaryocytes appeared. In the platelet precursor stage, obvious beaded reticular structures were seen, providing a basis for the subsequent formation of platelets ( Figure 1 ), in the HE differentiation stage, flow cytometry detected about 80% of CD34+ cells ( Figure 2 ), on the 12th day of differentiation, flow cytometry showed that about 90%-98% of the suspension cells expressed CD45 ( Figure 3 ), at the MKP stage of differentiation, there are about 60% CD41a+ / CD42b+ and 60% CD61+ / CD34- megakaryocyte progenitor cells ( Figure 4 ), at the MKP stage of differentiation, there are approximately 93% CD41a+ / CD42b+ and 96% CD61+ / CD34- megakaryocyte progenitor cells ( Figure 5 ).

[0151] Example 2 Exploration of differentiation time of megakaryocyte progenitor cells (MKP) and mature megakaryocytes (MMK)

[0152] 1. Experimental methods

[0153] In order to further optimize and shorten the differentiation time, we conducted detailed detection of different cell numbers and marker ratios in the MKP stage (i.e., the stage of differentiation of myeloid progenitor cells into megakaryotic progenitor cells) and the MMK stage (i.e., the stage of differentiation of megakaryotic progenitor cells into mature megakaryocytes).

[0154] 2. Experimental results

[0155] The results showed that the number of cells continued to increase during the MKP differentiation stage, but the growth trend of cells slowed down on the third day of differentiation. In addition, the number of cells no longer increased during the MMK stage ( Figure 7 A). The results of marker detection of MKP and MMK showed that the ratio of CD41+ / CD42+ cells gradually increased during the MKP differentiation stage, while the ratio of cells did not increase significantly starting from the second day of differentiation during the MMK stage ( Figure 7 B). Considering that the phenotype of platelet precursors begins to appear on the third day of cell differentiation in the MKP stage during differentiation, in order to avoid the early appearance of platelet precursors affecting subsequent platelet production, the MKP differentiation stage was shortened to 3 days (i.e., Day 12-Day 15 in Example 1), and the MMK stage was shortened to 2 days (i.e., Day 15-Day 17 in the example).

[0156] Example 3 Functional test of platelets prepared in Example 1

[0157] 1. Experimental methods

[0158] Platelet marker expression detection and platelet activation detection: conventional detection methods are used to detect the marker expression and platelet activation of iPSC-derived platelets (platelets prepared by the method described in Example 1 of the present invention) and donor-derived platelets.

[0159] Blood clot contraction experiment: The blood clot contraction ability was observed at 0.5 hr, 1 hr, 1.5 hr, 2 hr and 24 hours, and the blood clot volume formed by donor-derived platelets and iPSC-derived platelets (platelets prepared by the method described in Example 1 of the present invention) was compared.

[0160] Comparison of electron microscopic results: Comparison of electron microscopic results of donor-derived platelets and iPSC-derived platelets (platelets prepared by the method described in Example 1 of the present invention).

[0161] In vivo circulation experiment in mice: Donor-derived platelets and iPSC-derived platelets (platelets prepared by the method described in Example 1 of the present invention) were injected into the tail vein of mice, and orbital blood was collected at different time points of 0 hr, 0.5 hr, 1 hr, 4 hr, 6 hr and 24 hr to separate platelets and detect the proportion of exogenous platelets.

[0162] Platelet staining with rhodamine dye: Platelets were stained with rhodamine dye, and then iPSC-derived platelets (platelets prepared by the method described in Example 1 of the present invention) were injected into the tail vein of mice. The mice were anesthetized 0.5 hours after the injection, and the mice were dissected to remove the intestinal vein. A thrombosis model was prepared using 10% FeCl3, and thrombus aggregation in the modeled blood vessels was observed under a laser confocal microscope.

[0163] 2. Experimental results

[0164] The experimental results are as follows Figure 8-12 As shown, the results show that by comparing the surface markers of donor and iPSC-derived platelets, the proportion of CD61+ cells was 82% and 98%, respectively, and neither expressed CD34 and CD45. After adding the activator to activate, the proportion of PAC1+ cells in donor and iPSC-derived platelets was 57% and 88%, respectively. It can be seen that the iPSC-derived platelets prepared by the method described in Example 1 of the present invention have a higher activation efficiency than the donor platelets. At the same time, calcein AM was used for cell activity staining, and the activity ratios of donor and iPSC-derived platelets were 83% and 98%, respectively. It can be seen that the iPSC-derived platelets have higher activity than the donor-derived platelets ( Figure 8 ).

[0165] The results of the comparison of blood clot contraction between iPSC-derived platelets and donor-derived platelets showed that, compared with the blood clot volume formed by donor-derived platelets and iPSC-derived platelets (iPLT), the iPLT prepared by the method described in Example 1 of the present invention had a stronger contraction ability than the donor platelets ( Fig. 9 ).

[0166] Electron microscopic comparison of iPSC-derived platelets and donor-derived platelets showed that both donor-derived platelets and iPSC-derived platelets had obvious dense granules, α granules, open tubule systems, and mitochondrial structures ( Fig.10 ).

[0167] The results of the in vivo circulation experiment of iPSC-derived platelets and donor-derived platelets in mice showed that iPSC-derived platelets had a higher proportion of cells at 0.5 hours and a longer circulation time than donor-derived platelets ( Fig.11 ).

[0168] The results of the thrombosis function test of iPSC-derived platelets showed that obvious platelet aggregation could be observed in the thrombosis model blood vessels, indicating that the iPSC-derived platelets (iPLTs) prepared by the method described in Example 1 of the present invention have the ability to participate in thrombosis ( Fig.12 ).

[0169] Example 4 Screening for factors that promote megakaryocyte maturation

[0170] 1. Experimental methods

[0171] Day 15, megakaryocyte progenitor cells were treated with ROCKi (Y-27632), Blebbistin (BLE, i.e. (-)-Blebbistatin described in Example 1), FGF, EGF and AS2863619, respectively or in combination, and the cell morphology was observed (other experimental conditions were the same as in Example 1), wherein the dosage of each substance was: ROCKi (10 μM), BLE (10 μM), FGF (20 ng / mL), EGF (20 ng / mL), AS2863619 (2 μM). Megakaryocyte surface markers were detected by flow cytometry.

[0172] 2. Experimental results

[0173] The results showed that the cell volume of the experimental group treated with BLE or AS2863619 increased significantly compared with the control group, and the cell volume of the experimental group treated with BLE combined with ROCKi+BLE and AS+BLE was larger than that of the experimental group treated with BLE alone ( Fig.13A). The results of flow cytometry detection of megakaryocyte surface markers showed that the proportion of cells with high CD61 expression in the BLE, ROCKi+BLE and BLE+AS experimental groups increased significantly, and the proportion of CD41 and CD42 double positive cells also increased significantly. However, after AS treatment, the high expression of CD61 and the proportion of CD41+ / CD42+ cells decreased significantly ( Fig.13 B and Fig.13 C), and it was also observed that the ability of megakaryocytes to produce platelet precursors in the AS and AS+BLE groups was significantly reduced. In summary, the addition of ROCKi and BLE to treat megakaryocyte progenitor cells can significantly increase the proportion of megakaryocytes and promote platelet production.

[0174] Example 5 Optimization of FBS (fetal bovine serum) concentration

[0175] 1. Experimental methods

[0176] Adding serum during megakaryocyte maturation (Day 15-Day 17) and platelet formation (Day 17-Day 19) is beneficial to megakaryocyte differentiation and platelet maturation, and maintains platelet activity. In this example, the optimal concentration of serum added is determined by adjusting the serum concentration (other experimental conditions are the same as in Example 1).

[0177] 2. Experimental results

[0178] The results showed that there was no significant difference in the CD61+ / CD34- and CD41+ / CD42+ cell ratios of megakaryocytes after adding 15%, 10% and 5% serum, respectively. Fig.14 A). No significant difference was observed in cell morphology ( Fig.14 B). In addition, when different concentrations of serum were added to the platelets at the platelet stage, there was no significant difference in the ratio of CD61+ / PAC1+ cells after PMA activation. Calcein AM staining was used to detect cell activity. The results showed that there was no difference in platelet activity under different serum concentrations ( Fig.14 D). At the same time, the MMK and platelet counts at different serum concentrations were also statistically analyzed, and the results showed no significant difference ( Fig.14 C). The above results indicate that active platelets can be obtained using a serum concentration of 5%.

Claims

1. A culture system for inducing iPSC differentiation to obtain megakaryocytes and / or platelets, characterized in that: The culture system includes a culture medium for iPSC differentiation to form embryoid bodies, a culture medium for embryoid bodies to differentiate into mesoderm, a culture medium for mesoderm to differentiate into hemogenic endothelial cells, a culture medium for hemogenic endothelial cells to differentiate into myeloid progenitor cells, a culture medium for myeloid progenitor cells to differentiate into megakaryotic progenitor cells, a culture medium for megakaryotic progenitor cells to differentiate into mature megakaryocytes, and / or a culture medium for megakaryocytes to differentiate into platelets; Preferably, the iPSC differentiation to form embryoid bodies culture medium comprises a basal culture medium, a ROCK pathway inhibitor, and PVA; Preferably, the embryoid body to mesoderm differentiation medium comprises a basal medium and a GSK3β inhibitor; Preferably, the mesoderm to hemogenic endothelial cell differentiation medium comprises M1 medium and M2 medium; Preferably, the medium for differentiating hemogenic endothelial cells into myeloid progenitor cells comprises M3 medium; Preferably, the culture medium for differentiating myeloid progenitor cells into megakaryotic progenitor cells comprises M4 culture medium; Preferably, the medium for differentiating megakaryocyte progenitor cells into mature megakaryocytes comprises M5 medium; Preferably, the megakaryocyte differentiation medium to form platelets comprises M6 medium; More preferably, the basal medium in the iPSC differentiation to form embryoid bodies culture medium includes E8 medium, complete medium, StemSpan TM SFEM Hematopoietic Cell Culture Medium、StemPro-34、 II. STEMdiff TM APEL TM 2 Medium and / or BPEL; More preferably, the ROCK pathway inhibitor includes Y-27632, Thiazovivin, Fasudil HCl, GSK429286A, RKI-1447, and / or Azaindole 1; Most preferably, the basal medium in the iPSC differentiation to form embryoid bodies culture medium is E8 medium or complete medium; Most preferably, the ROCK pathway inhibitor is Y-27632; Most preferably, the iPSC differentiation to form embryoid bodies culture medium is E8 culture medium containing Y-27632 or complete culture medium containing PVA; More preferably, the basal medium in the embryoid body to mesoderm differentiation medium includes E8 medium, complete medium, StemSpan TM SFEM Hematopoietic Cell Culture Medium、StemPro-34、 II. STEMdiff TM APEL TM 2 Medium and / or BPEL; More preferably, the GSK3β inhibitor includes Chir99021, SB216763, CHIR-98014, TWS119, Tideglusib, and / or SB415286; Most preferably, the basal medium in the embryoid body to mesoderm differentiation medium is E8 medium; Most preferably, the GSK3β inhibitor is Chir99021; Most preferably, the embryoid body to mesoderm differentiation medium is E8 complete medium containing Chir99021; Preferably, the M1 medium in the mesoderm-to-hemogenic endothelial cell differentiation medium contains STEMdiff TM APEL TM 2Medium or (DMEM / F12, IMDM, L-glutamine, ascorbic acid, monothioglycerol, PFHMII, BSA or HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine), BMP4, VEGF, bFGF; Preferably, the M2 medium in the mesoderm-to-hemogenic endothelial cell differentiation medium comprises M1 medium, inhibitors of TGF-β type I receptor ALK5, ALK4 and ALK7; More preferably, the inhibitors of TGF-β type I receptor ALK5, ALK4 and ALK7 include SB431542, Galunisertib, LY2109761, SB525334, SB505124, and / or GW788388; Most preferably, the inhibitor of TGF-β type I receptor ALK5, ALK4 and ALK7 is SB431542; Preferably, the M3 medium in the hemogenic endothelial cell differentiation medium to myeloid progenitor cell contains APEL or (DMEM / F12, IMDM, L-glutamine, ascorbic acid, thioglycerol, PFHMII, BSA or HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine), β-mercaptoethanol, VEGF, bFGF, SCF, IL-3, TPO, IL-6, IL-11; Preferably, the M4 medium in the medium for differentiation of myeloid progenitor cells into megakaryotic progenitor cells contains StemSpan TM SFEM Hematopoietic Cell Culture Medium or STEMdiff TM APEL TM 2 Medium or (DMEM / F12, IMDM, L-glutamine, ascorbic acid, monothioglycerol, PFHMII, BSA or HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine), IL-6, IL-11, SCF, sodium heparin, TPO or TA316; Preferably, the M5 medium in the medium for differentiating megakaryocyte progenitor cells into mature megakaryocytes contains IMDM, serum, L-glutamine, ascorbic acid, 1×Insulin-Transferrin-Selenium-Ethanolamine, thioglycerol, SCF, TA316 or TPO, GM6001, SR1, Y-27632, (-)-Blebbistatin; More preferably, the serum comprises FBS, KSR, HSA, and / or HPL; Most preferably, the serum is FBS; Preferably, the M6 ​​medium in the megakaryocyte differentiation medium to form platelets contains IMDM, serum, L-glutamine, ascorbic acid, 1×Insulin-Transferrin-Selenium-Ethanolamine, thioglycerol, SCF, TA316 or TPO, GM6001, SR1, and Y-27632; More preferably, the serum comprises FBS, KSR, HSA, and / or HPL; Most preferably, the serum is FBS.

2. The culture system according to claim 1, characterized in that The contents of the components in the iPSC differentiation embryoid body culture medium are: (1-50) μM Y-27632, (0.05-10) mg / mL PVA; Preferably, the contents of the components in the iPSC differentiation to form embryoid bodies medium are: 10 μM Y-27632, 2 mg / mL PVA; Preferably, the contents of the components in the embryoid body to mesoderm differentiation medium are: (1-10) μM Chir99021; More preferably, the contents of the components in the embryoid body to mesoderm differentiation medium are: 10 μM Chir99021; Preferably, the contents of the components in the M1 medium in the mesoderm-to-hemogenic endothelial cell differentiation medium are: TM APEL TM 2 Medium or (35-55)% DMEM / F12, (35-55)% IMDM, (0.01-10)% L-glutamine, (25-75) μg / mL ascorbic acid, (0.05-10) mM thioglycerol, (1-10)% PFHMII, (1-10) mg / mL BSA or (0.05-10)% HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine, (25-75) ng / mL BMP4, (25-75) ng / mL VEGF, (25-75) ng / mL bFGF; More preferably, the contents of the components in the M1 medium in the mesoderm-to-hemogenic endothelial cell differentiation medium are: TM APEL TM 2 Medium or 44.15% DMEM / F12, 44.15% IMDM, 1% L-glutamine, 50 μg / mL ascorbic acid, 0.4 mM thioglycerol, 5% PFHMII, 2.5 mg / mL BSA or 1.25% HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine, 50 ng / mL BMP4, 50 ng / mL VEGF, 50 ng / mL bFGF; Preferably, the content of SB431542 in the M2 medium in the mesoderm-to-hemogenic endothelial cell differentiation medium is: (1-9) μM; More preferably, the content of SB431542 in the M2 medium in the mesoderm to hemogenic endothelial cell differentiation medium is: 6 μM; Preferably, the contents of the components in the M3 medium in the hemogenic endothelial cell to myeloid progenitor cell differentiation medium are: APEL or (35-55)% DMEM / F12, (35-55)% IMDM, (0.01-10)% L-glutamine, (25-75) μg / mL ascorbic acid, (0.05-10) mM thioglycerol, (1-10)% PFHMII, (1-10) mg / mL BSA or (0.05-10)% HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine, (25-75) μM β-mercaptoethanol, (25-75) ng / mL VEGF, (25-75) ng / mL bFGF, (25-75) ng / mL SCF, (1-50) ng / mL IL-3, (25-75)ng / mL TPO, (1-50)ng / mL IL-6, (1-50)ng / mL IL-11; More preferably, the contents of the components in the M3 medium in the medium for differentiating hemogenic endothelial cells into myeloid progenitor cells are: APEL or 44.15% DMEM / F12, 44.15% IMDM, 1% L-glutamine, 50 μg / mL ascorbic acid, 0.4 mM thioglycerol, 5% PFHMII, 2.5 mg / mL BSA or 1.25% HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine, 55 μM β-mercaptoethanol, 50 ng / mL VEGF, 50 ng / mL bFGF, 50 ng / mL SCF, 20 ng / mL IL-3, 50 ng / mL TPO, 20 ng / mL IL-6, 20 ng / mL IL-11; Preferably, the contents of the components in the M4 medium in the medium for myeloid progenitor cells to differentiate into megakaryocyte progenitor cells are: StemSpan TM SFEM Hematopoietic Cell Culture Medium or STEMdiff TM APEL TM 2 Medium or (35-55)% DMEM / F12, (35-55)% IMDM, (0.01-10)% L-glutamine, (25-75) μg / mL ascorbic acid, (0.05-10) mM thioglycerol, (1-10)% PFHMII, (1-10) mg / mL BSA or (0.05-10)% HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine, (1-50) ng / mL IL-6, (1-50) ng / mL IL-11, (25-75) ng / mL SCF, (1-50) U / mL heparin sodium, (25-75) ng / mL TPO or (100-300) ng / mL TA316; More preferably, the contents of the components in the M4 medium in the medium for myeloid progenitor cells to differentiate into megakaryocyte progenitor cells are: StemSpan TM SFEM Hematopoietic Cell Culture Medium or STEMdiff TM APEL TM 2Medium or 44.15% DMEM / F12, 44.15% IMDM, 1% L-glutamine, 50 μg / mL ascorbic acid, 0.4 mM thioglycerol, 5% PFHMII, 2.5 mg / mL BSA or 1.25% HSA, 1×Insulin-Transferrin-Selenium-Ethanolamine, 20 ng / mL IL-6, 20 ng / mL IL-11, 50 ng / mL SCF, 10 U / mL heparin sodium, 50 ng / mL TPO or 200 ng / mL TA316; Preferably, the contents of the components in the M5 medium in the medium for differentiating megakaryocyte progenitor cells into mature megakaryocytes are: IMDM, (2-20)% FBS, (0.01-10)% L-glutamine, (25-75) μg / mL ascorbic acid, 1×Insulin-Transferrin-Selenium-Ethanolamine, (0.01-10) mM thioglycerol, (1-50) ng / mL SCF, (100-300) ng / mL TA316 or (25-75) ng / mL TPO, (1-50) μM GM6001, (0.01-5) μM SR1, (1-20) μM Y-27632, (1-20) μM (-)-Blebbistatin; More preferably, the contents of the components in the M5 medium in the medium for differentiating megakaryocyte progenitor cells into mature megakaryocytes are: IMDM, 5% FBS, 1% L-glutamine, 50 μg / mL ascorbic acid, 1×Insulin-Transferrin-Selenium-Ethanolamine, 0.4 mM thioglycerol, 20 ng / mL SCF, 200 ng / mL TA316 or 50 ng / mL TPO, 20 μM GM6001, 0.75 μM SR1, 10 μM Y-27632, 10 μM (-)-Blebbistatin; Preferably, the contents of the components in the M6 ​​medium in the megakaryocyte differentiation into platelet medium are: IMDM, (2-20)% FBS, (0.01-10)% L-glutamine, (25-75) μg / mL ascorbic acid, 1×Insulin-Transferrin-Selenium-Ethanolamine, (0.01-5) mM thioglycerol, (1-50) ng / mL SCF, (100-300) ng / mL TA316 or (25-75) ng / mL TPO, (1-50) μM GM6001, (0.01-5) μM SR1, (1-20) μM Y-27632; More preferably, the contents of the components in the M6 ​​medium in the megakaryocyte differentiation into platelet medium are: IMDM, 5% FBS, 1% L-glutamine, 50 μg / mL ascorbic acid, 1×Insulin-Transferrin-Selenium-Ethanolamine, 0.4 mM thioglycerol, 20 ng / mL SCF, 200 ng / mL TA316 or 50 ng / mL TPO, 20 μM GM6001, 0.75 μM SR1, and 10 μM Y-27632.

3. A method for inducing iPSC differentiation to obtain megakaryocytes and / or platelets, characterized in that: The method comprises the following steps: using the culture system described in claim 1 or 2 to culture and differentiate iPSCs.

4. The method according to claim 3, characterized in that The method comprises the following steps: (1) Day-1, iPSC differentiation to form embryoid bodies stage, iPSCs are cultured using the iPSC differentiation to form embryoid bodies medium described in claim 1 or 2; (2) Day 0, embryoid body differentiation to mesoderm stage, culturing the culture product obtained in step (1) using the embryoid body to mesoderm differentiation medium described in claim 1 or 2; (3) Day 1 to Day 3, the stage of differentiation of mesoderm into hemogenic endothelial cells, using the M1 medium or M2 medium described in claim 1 or 2 to culture the culture product obtained in step (2); (4) Day 4 to Day 12, the differentiation stage of hemogenic endothelial cells into myeloid progenitor cells, culturing the culture product obtained in step (3) using the M3 medium described in claim 1 or 2; (5) Day 12-Day 15, myeloid progenitor cells differentiate into megakaryotic progenitor cells, and the culture product obtained in step (4) is cultured using the M4 medium described in claim 1 or 2; (6) Day 15-Day 17, the stage of differentiation of megakaryocyte progenitor cells into mature megakaryocytes, culturing the culture product obtained in step (5) using the M5 medium described in claim 1 or 2; (7) Day 17, the stage of megakaryocyte differentiation into platelets, the culture product obtained in step (6) is cultured using the M6 ​​culture medium described in claim 1 or 2 to obtain platelets.

5. The method according to claim 4, characterized in that The cell density of iPSC in step (1) is 1.0×10 5 -2×10 5 / mL; Preferably, the culture conditions in step (1) are 5% CO2, 37°C, 24h; Preferably, the culture conditions in step (2) are 5% CO2, 90% N2, 37°C, 24h; Preferably, step (3) comprises the following steps: Day 1, replacing the culture medium with M1 culture medium; Day 2, replacing the culture medium with M2 culture medium; Day 3, half-changing the culture medium; More preferably, the culture conditions in step (3) are 5% CO2, 90% N2, 37°C, 24h.

6. The method according to claim 4, characterized in that The culture conditions in step (4) are 5% CO2 and 37°C; Preferably, the culture conditions in step (4) are suspension culture or adherent culture; More preferably, the adherent culture uses a cell culture dish pre-coated with a culture dish coating matrix; Most preferably, the culture dish coating matrix comprises Matrigel, Geltin, Lamin521, and / or Fibronection; Most preferably, the culture dish coating matrix is ​​Matrigel; More preferably, the medium is changed once every 3.5 days in step (4); Preferably, the culture conditions in step (5) are 5% CO2 and 37°C; Preferably, the cell density of the cells in step (5) is 1.0×10 4 -10×10 4 / mL; More preferably, the cell density of the cells in step (5) is 5.0×10 4 / mL; Preferably, the culture conditions in step (5) are suspension culture or adherent culture; More preferably, the adherent culture is performed in an uncoated culture dish.

7. The method according to claim 4, characterized in that The culture conditions in step (6) are 5% CO2 and 37°C; Preferably, the cell density of the cells in step (6) is 1.0×10 5 -3.0×10 5 / mL; Preferably, the culture conditions in step (6) are suspension culture or adherent culture; Preferably, the culture conditions in step (7) are 5% CO2 and 37°C; Preferably, the cell density of the cells in step (7) is 1.0×10 5 -10×10 5 / mL; More preferably, the cell density of the cells in step (7) is 5×10 5 / mL; Preferably, the culture conditions in step (7) are suspension culture or adherent culture.

8. Any of the following methods, characterized in that The method comprises: (1) A method for improving the differentiation efficiency of iPSCs into megakaryocytes, characterized in that the method comprises the following steps: culturing and differentiating iPSCs using the culture system according to claim 1 or 2; Preferably, the steps are steps (1)-(6) as described in any one of claims 3-7; (2) A method for improving the differentiation efficiency of iPSC into platelets, characterized in that the method comprises the following steps: culturing and differentiating iPSC using the culture system described in claim 1 or 2; Preferably, the steps are steps (1)-(7) as described in any one of claims 3-7.

9. The application of any one of the following aspects, characterized in that: The applications include: (1) Use of the culture system according to claim 1 or 2 in inducing iPSC differentiation to obtain megakaryocytes and / or platelets; (2) Use of the megakaryocytes and / or platelets prepared by the method of any one of claims 3 to 7 in the preparation of a drug for treating diseases associated with low megakaryocytes and / or platelets.

10. A pharmaceutical preparation, characterized in that The pharmaceutical preparation comprises megakaryocytes and / or platelets prepared by the method according to any one of claims 3-7.

Citation Information

Patent Citations

  • Methods for production of platelets from pluripotent stem cells and compositions thereof

    CN105101979A

  • Culture medium and method for inducing iPSC (induced pluripotent stem cell) differentiation to obtain macrophages and application of culture medium and method

    CN115433715A

  • Kit for inducing stem cells to differentiate into megakaryocytes and / or platelets and application thereof

    CN115786259A

  • Combination of pharmacological and microfluidic features for improved platelets production

    US20180104692A1

Cited By

  • Application of in-vitro regenerated platelets to treatment of premature ovarian insufficiency

    CN120392818A

  • Application of in vitro regenerated platelets in the treatment of premature ovarian insufficiency

    CN120392818B

  • Method for improving quality of platelets produced in vitro

    CN121472141A